Duchenne Muscular Dystrophy Epidemiology Forecast Report

DelveInsight’s ‘Duchenne Muscular Dystrophy (DMD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy (DMD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Duchenne Muscular Dystrophy (DMD) Understanding

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is a genetic disorder characterized by progressive muscle degeneration and weakness. It is one of nine types of muscular dystrophy.

DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3–5. The disease primarily affects boys, but in rare cases it can affect girls. DMD is inherited as an X-linked disease. X-linked genetic disorders are conditions caused by an abnormal gene on the X chromosome and manifest mostly in males. Females that have a defective gene present on one of their X chromosomes are carriers for that disorder. Carrier females usually do not display symptoms because females have two X chromosomes and only one carries the defective gene. Males have one X chromosome that is inherited from their mother and if a male inherits an X chromosome that contains a defective gene he will develop the disease.

The clinical hallmarks of DMD include weakness and wasting of various voluntary muscles of the body. In most advanced stages of the disease, the heart and gut muscles will be affected. Symptoms of DMD are usually noticed in boys between 1–6 years of age. A steady decline occurs in muscle strength between the ages of 6–11 years. By age 10, braces may be needed for walking. By age 13, most boys with DMD are using a wheelchair full-time. Children with DMD are often late walkers. In toddlers, parents may notice enlarged calf muscles. This enlargement is known as pseudohypertrophy, or "false enlargement," because the muscle tissue is abnormal and may contain scar tissue. A preschooler with DMD may seem clumsy and fall often. Parents also may note that children have trouble climbing stairs, getting up from the floor or running.

Duchenne Muscular Dystrophy (DMD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Population of Duchenne Muscular Dystrophy, Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy, Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy and Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Duchenne Muscular Dystrophy (DMD) Detailed Epidemiology Segmentation

• The total diagnosed prevalent population of Duchenne Muscular Dystrophy (DMD) in the 7 major markets was found to be 27,685 in 2017. In case of DMD patients in the United States, the diagnosed prevalent cases were 16,840 in 2017.

• The total diagnosed prevalent cases of Duchenne Muscular Dystrophy (DMD) patients were found to be maximum in the age-group 8–13 year and 14–19 year in the United States, which was 4,757 and 4,714 respectively in 2017.

• In EU5 countries the diagnosed prevalence was found to be 27,685 in 2017 which is expected to rise in the forecast period 2020–2030.

Scope of the Report

• The report covers the descriptive overview of Duchenne Muscular Dystrophy (DMD), explaining its causes, signs and symptoms, pathophysiology.

• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.

• The report assesses the disease risk and burden and highlights the unmet needs of Duchenne Muscular Dystrophy (DMD).

• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Duchenne Muscular Dystrophy (DMD), Total Diagnosed and Treated Cases of Duchenne Muscular Dystrophy (DMD).

Report Highlights

• Eleven Year Forecast of Duchenne Muscular Dystrophy (DMD)

• 7MM Coverage

• Diagnosed Prevalent Population of Duchenne Muscular Dystrophy

• Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy. Different age groups have been considered to develop the forecast model such as 2–7, 8–13, 20–25 and >25. Out of which the highest diagnosed prevalent age group was 8–13 years old.

• Report also covers Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy, including several mutations such as Large Mutations, Small Mutations and Point Mutations with major proportion for deletions in Large Mutations subgroup.

• Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy. DelveInsight has also estimated ocuurence of associated comorbidities due to DMD, which include Attention-deficit hyperactivity disorder (ADHD), Autism spectrum disorder (ASD), Cardiomyopathy and others.

Key Questions Answered

• What is the disease risk, burden and unmet needs of Duchenne Muscular Dystrophy (DMD)?

• What is the historical Duchenne Muscular Dystrophy (DMD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

• What would be the forecasted patient pool of Duchenne Muscular Dystrophy (DMD) at the 7MM level?

• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Duchenne Muscular Dystrophy (DMD)?

• Out of the above-mentioned countries, which country would have the highest prevalent population of Duchenne Muscular Dystrophy (DMD) during the forecast period (2020–2030)?

• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy

The Duchenne Muscular Dystrophy (DMD) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Duchenne Muscular Dystrophy (DMD) market.

• Quantify patient share distribution in the 7MM for Duchenne Muscular Dystrophy (DMD).

• The Duchenne Muscular Dystrophy (DMD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.

• The Duchenne Muscular Dystrophy (DMD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation

• Disease Risk and Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

Geographies Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

1 Key Insights

2 Duchenne Muscular Dystrophy (DMD) Market Overview at a Glance

3 Disease Background and Overview: Duchenne Muscular Dystrophy (DMD)

3.1 Introduction

3.2 Clinical Manifestations

3.3 Causes

3.3.1 Occurrence of Duchenne in Family

3.4 Inheritance of DMD

3.4.1 Females and DMD

3.5 Pathophysiology

3.6 Biomarkers

3.6.1 Tissue Composition

3.6.2 Genetic Makers

3.6.3 Proteins

3.6.4 Lipids and Metabolites

3.6.5 MicroRNA

3.7 Risk Factors

3.8 Diagnosis

3.9 Disease Progression

4 Recognized Establishments

4.1 United States

4.2 Europe

4.3 Japan

5 Epidemiology and Patient Population

5.1 Key Findings

5.1 7MM Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD)

6 Country Wise-Epidemiology of Duchenne Muscular Dystrophy (DMD)

6.1 United States

6.1.1 Assumptions and Rationale

6.1.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States

6.1.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States

6.1.4 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States

6.1.5 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United States

6.2 EU5 Countries

6.2.1 Assumptions and Rationale

6.3 Germany

6.3.1 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany

6.3.2 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany

6.3.3 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany

6.3.4 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Germany

6.4 France

6.4.1 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France

6.4.2 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France

6.4.3 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France

6.4.4 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in France

6.5 Italy

6.5.1 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy

6.5.2 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy

6.5.3 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy

6.5.4 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Italy

6.6 Spain

6.6.1 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain

6.6.2 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain

6.6.3 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain

6.6.4 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Spain

6.7 United Kingdom

6.7.1 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom

6.7.2 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom

6.7.3 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom

6.7.4 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United Kingdom

6.8 Japan

6.8.1 Assumptions and Rationale

6.8.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan

6.8.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan

6.8.4 Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan

6.8.5 Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Japan

7 Appendix

7.1 Bibliography

7.2 Report Methodology

8 DelveInsight Capabilities

9 Disclaimer

10 About DelveInsight

Table 1: Total Diagnosed Prevalent Population of DMD in the 7MM (2017–2030)

Table 2: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States (2017–2030)

Table 3: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017–2030)

Table 4: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017–2030)

Table 5: Diagnosed Prevalence of Associated Comorbidties in DMD in the United States (2017–2030)

Table 6: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Table 7: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Table 8: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Table 9: Diagnosed Prevalence of Associated Comorbidties in DMD in Germany (2017–2030)

Table 10: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Table 11: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Table 12: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Table 13: Diagnosed Prevalence of Associated Comorbidties in DMD in France (2017–2030)

Table 14: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Table 15: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Table 16: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Table 17: Diagnosed Prevalence of Associated Comorbidties in DMD in Italy (2017–2030)

Table 18: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Table 19: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Table 20: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Table 21: Diagnosed Prevalence of Associated Comorbidties in DMD in Spain (2017–2030)

Table 22: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Table 23: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Table 24: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Table 25: Diagnosed Prevalence of Associated Comorbidties in DMD in the United Kingdom(2017–2030)

Table 26: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

Table 27: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

Table 28: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

Table 29: Diagnosed Prevalence of Associated Comorbidties in DMD in Japan (2017–2030)

Figure 1: Cause of DMD

Figure 2: Inheritance of DMD

Figure 3: Biomarker types used for clinical management of DMD

Figure 4: Biomarker types used for clinical management of DMD

Figure 5: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM (2017–2030)

Figure 6: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States (2017–2030)

Figure 7: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017–2030)

Figure 8: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017–2030)

Figure 9: Diagnosed Prevalence of Associated Comorbidties in DMD in the United States (2017–2030)

Figure 10: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Figure 11: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Figure 12: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Figure 13: Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Germany (2017–2030)

Figure 14: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Figure 15: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Figure 16: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Figure 17: Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in France (2017–2030)

Figure 18: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Figure 19: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Figure 20: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Figure 21: Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Italy (2017–2030)

Figure 22: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Figure 23: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Figure 24: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Figure 25: Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Spain (2017–2030)

Figure 26: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Figure 27: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Figure 28: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Figure 29: Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017–2030)

Figure 30: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

Figure 31: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

Figure 32: Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

Figure 33: Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Japan (2017–2030)

  • Tags:
  • Duchenne Muscular Dystrophy Epidemi...
  • Duchenne Muscular Dystrophy
  • Duchenne Muscular Dystrophy Pipeli...
  • Duchenne Muscular Dystrophy Compan...
  • Duchenne Muscular Dystrophy preval...
  • Duchenne Muscular Dystrophy incide...
  • Duchenne Muscular Dystrophy patien...
  • Duchenne Muscular Dystrophy treatm...

Forward to Friend

Need A Quote